Kinshukai Infusion Clinic

Osaka 530-0011

0 studies enrolling now · 18 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Fistulizing Crohns Disease, Moderately to Severely Active Crohns Disease, Perianal Crohns Disease, Ulcerative Colitis

Studies at this site

• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) — Stopped early
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early